Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) received an FDA Complete Response Letter (CRL) for its resubmitted oxylanthanum carbonate (OLC) NDA for treating hyperphosphatemia in CKD patients on dialysis.

The CRL cites previously identified third-party manufacturing deficiencies; FDA raised no efficacy or safety concerns and requested no new data. Label and packaging discussions are ongoing.

Positive

• FDA raised no concerns about OLC’s clinical efficacy or safety and requested no additional data
• OLC NDA is supported by three clinical studies, multiple preclinical studies, and CMC data
• Labeling and packaging discussions with FDA are active, including June 29 communication on labels

Negative

• FDA issued a Complete Response Letter on the resubmitted OLC NDA on June 30, 2026
• CRL is based on unresolved deficiencies at the original third-party manufacturing vendor
• FDA has not yet conducted its inspection of the third-party manufacturing facility

News Market Reaction – UNCY

-39.09% 2.3x vol

34 alerts

-39.09% Session close to close

-53.1% Trough in 3 hr 31 min

$205.59M Market Cap

2.3x Rel. Volume

In the Jun 30 session, UNCY declined 39.09%, reflecting a significant negative market reaction. Argus tracked a trough of -53.1% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -39.1% in the session following this news. A negative reaction despite positive ef...

Analysis

The stock dropped -39.1% in the session following this news. A negative reaction despite positive efficacy and safety commentary fits prior clinical updates, which averaged -2.85%. However, an effective $150,000,000 shelf and elevated short interest may complicate any post‑selloff stabilization, especially around future FDA or financing milestones.

Key Figures

Clinical studies supporting NDA: 3 studies Phase 1 study: Phase 1 FDA communication date: June 29

3 metrics

Clinical studies supporting NDA 3 studies Phase 1, bioequivalence, and tolerability studies for OLC

Phase 1 study Phase 1 Conducted in healthy volunteers for OLC

FDA communication date June 29 Latest FDA feedback on carton and container label before CRL

Previous Clinical trial Reports

5 past events · Latest: Jan 29 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 29	NDA resubmission accepted	Positive	-5.0%	FDA accepted OLC NDA resubmission with a new PDUFA target date.
Dec 29	NDA resubmission filed	Positive	-2.3%	Company resubmitted the OLC NDA after addressing vendor compliance issues.
Oct 28	Type A meeting update	Positive	-9.9%	Reported constructive FDA Type A meeting and plan to resubmit OLC NDA.
Feb 20	Preclinical combo data	Positive	+2.4%	Preclinical data showed phosphate reduction with OLC plus tenapanor.
Oct 09	UNI-494 Phase 1 complete	Positive	+0.6%	Successful completion of UNI-494 Phase 1 in healthy volunteers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical and regulatory OLC updates have often seen negative price reactions despite generally positive or progress-oriented news.

Key Terms

complete response letter, new drug application (nda), hyperphosphatemia, type a meeting, +2 more

6 terms

complete response letter regulatory

"announced that it has received a Complete Response Letter (CRL) from the U.S. Food"

A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.

new drug application (nda) regulatory

"resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC) for the treatment"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

hyperphosphatemia medical

"oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in patients with"

An elevated level of phosphate in the blood, often caused by reduced kidney function or certain medications, that can harm bones, blood vessels and organs if untreated. Investors should care because prevalence, safety concerns and regulatory scrutiny around treatments or diagnostics for this condition can drive demand, affect clinical trial outcomes, influence healthcare spending and change a company’s revenue and risk profile—similar to how a common road hazard can change demand for safety products.

type a meeting regulatory

"discussed these milestones during a Type A meeting with the FDA in September"

A Type A meeting is an urgent, short-notice session requested between a company and a regulatory agency (for example, the FDA in the U.S.) to resolve critical issues that block a development program, such as a clinical hold or safety concern. Investors care because the outcome can immediately affect whether a clinical trial or approval process resumes, changing timelines, costs and the company’s near-term value — like calling an emergency mechanic when a car won’t start so a trip can continue.

bioequivalence technical

"The OLC NDA is supported by data from three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study"

When two medicines deliver the same amount of active ingredient into the bloodstream at about the same speed and level, they are considered bioequivalent. Investors care because bioequivalence is the regulatory test that allows generic or reformulated drugs to replace branded products without new safety trials, often opening large, lower‑cost market opportunities and changing a drug maker’s sales and competitive position—like two recipes that taste the same but sell at different prices.

chemistry, manufacturing and controls (cmc) regulatory

"multiple preclinical studies, as well as chemistry, manufacturing and controls (CMC) data."

Chemistry, manufacturing and controls (CMC) is the set of scientific and operational steps that show how a drug or biologic is made, what goes into it, and how its quality is consistently checked—think of it as the recipe, the factory process, and the quality checklist for a medicine. Investors care because strong CMC reduces risks around regulatory approval, production delays, batch failures and unexpected costs, directly affecting a product’s ability to reach market and generate revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor --

-- FDA inspection of third-party facility did not occur during the NDA resubmission review --

-- Labeling discussions currently underway; latest communication received by the Company from FDA on June 29 regarding carton and container label --

-- FDA did not raise concerns regarding the clinical efficacy or safety data of OLC, and no additional data was requested --

MOUNTAIN VIEW, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The FDA has not raised any concerns regarding clinical efficacy or safety data, and no additional data was requested from Unicycive.

The CRL is based on the same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025. Unicycive understands that the FDA has not yet conducted its inspection of that third-party manufacturing vendor as part of the review process of the resubmitted NDA. The NDA for OLC had been resubmitted based on Unicycive’s belief of continued progress by the original third-party manufacturing vendor in resolving FDA-cited deficiencies and demonstrating inspection readiness. Unicycive previously discussed these milestones during a Type A meeting with the FDA in September 2025, which was held to obtain feedback and alignment on resolving the deficiencies identified in the Company’s CRL related to the compliance status of the vendor. The FDA did not express any concerns about the third-party manufacturer’s progress and no additional issues were raised by the FDA at the Type A meeting.

“We remain confident in the efficacy and safety of OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “We are in active and ongoing discussion with the FDA regarding label and packaging, and we are optimistic that there will be a successful inspection of the third-party manufacturing vendor and that we will be able to expeditiously resubmit the NDA.”

The OLC NDA is supported by data from three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in chronic kidney disease (CKD) patients on dialysis, multiple preclinical studies, as well as chemistry, manufacturing and controls (CMC) data.

About Oxylanthanum Carbonate
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.¹ Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

¹Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.

About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:
Layne Cosgrove
Real Chemistry
llitsinger@realchemistry.com

FAQ

What did the FDA’s June 30, 2026 Complete Response Letter mean for Unicycive (UNCY) oxylanthanum carbonate NDA?

The FDA issued a Complete Response Letter for Unicycive’s resubmitted OLC NDA, citing third-party manufacturing deficiencies. According to Unicycive, the agency did not raise concerns about clinical efficacy or safety and did not request additional data, but the NDA remains under resolution efforts.

Did the FDA request new clinical data for Unicycive (UNCY) oxylanthanum carbonate in the 2026 CRL?

No, the FDA did not request new clinical data for OLC in the 2026 CRL. According to Unicycive, the agency raised no efficacy or safety concerns, focusing instead on previously identified deficiencies at the third-party manufacturing vendor supporting the NDA.

What third-party manufacturing issues affected Unicycive (UNCY) oxylanthanum carbonate NDA in the latest FDA CRL?

The CRL is based on the same third-party manufacturing deficiencies cited in a June 2025 letter. According to Unicycive, the FDA has not yet inspected that vendor during the resubmission review, leaving the compliance status of the manufacturing facility unresolved for the current NDA.

How is Unicycive (UNCY) working with the FDA on oxylanthanum carbonate labeling and packaging?

Unicycive reports active, ongoing discussions with the FDA regarding label and packaging for OLC. According to Unicycive, the latest FDA communication on June 29 addressed carton and container labels, indicating labeling review is progressing alongside efforts to resolve manufacturing-related deficiencies.

What clinical data support Unicycive (UNCY) oxylanthanum carbonate NDA for CKD patients on dialysis?

The OLC NDA is supported by three clinical studies plus multiple preclinical and CMC data packages. According to Unicycive, these include a Phase 1 study, a bioequivalence study in healthy volunteers, and a tolerability study in chronic kidney disease patients on dialysis.

Did the FDA express concerns about Unicycive (UNCY) manufacturing vendor progress before the 2026 CRL?

During a September 2025 Type A meeting, the FDA did not express concerns about the third-party manufacturer’s progress. According to Unicycive, no additional issues were raised then, though the latest CRL still references the vendor’s previously cited deficiencies and pending inspection.